NEW YORK (GenomeWeb) – OncoDNA said today that CyberKnife Sigulda will market and distribute its tumor profiling solutions for clinical use in Latvia.

Financial and other terms of the deal were not disclosed.

Gosselies, Belgium-based OncoDNA's solutions guide oncologists in their treatment decision-making based on a solid or liquid molecular characterization of a tumor. They include tumor interrogation technologies — such as NGS, immunohistochemistry, and pyrosequencing — combined with an extensive clinical literature assessment, the firm said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.